Brain metabolite alterations in Eisenmenger syndrome: Evaluation with MR proton spectroscopy
| Autor: | Erol Bozdogan, Ali Yildirim, Dilek Sen Dokumaci, Ferit Dogan, Bülent Koca, Fatıma Nurefşan Boyacı |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
In vivo magnetic resonance spectroscopy medicine.medical_specialty Magnetic Resonance Spectroscopy Adolescent Lentiform nucleus Choline Metabolite Metabolite Thalamus 030204 cardiovascular system & hematology Choline White matter 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine Humans Radiology Nuclear Medicine and imaging Child Hypoxia Brain Aspartic Acid business.industry Brain General Medicine Eisenmenger Complex Creatine medicine.disease Magnetic Resonance Imaging Pulmonary hypertension Frontal Lobe medicine.anatomical_structure chemistry Case-Control Studies Child Preschool Eisenmenger syndrome Anesthesia Cardiology Female Protons business Biomarkers 030217 neurology & neurosurgery |
| Zdroj: | European Journal of Radiology. 86:70-75 |
| ISSN: | 0720-048X |
| DOI: | 10.1016/j.ejrad.2016.11.005 |
| Popis: | Objective Eisenmenger syndrome (ES) is a life-threatening disease characterized by pulmonary hypertension and cyanosis in patients with congenital heart diseases. The aim of this study was to determine the brain metabolite changes in Eisenmenger syndrome compared with a control group using MR proton spectroscopy. Methods and Materials The study included 10 children (3 male, 7 female) with congenital heart diseases and a diagnosis of Eisenmenger syndrome. The control group consisted of 10 healthy volunteer children. All were examined with a 1.5 T MRI scanner and single voxel spectroscopy was performed to obtain spectra from three different regions; left frontal subcortical white matter, left lentiform nucleus and left thalamus. Peak integral values obtained from the spectra were used as quantitative data. Results The ages of the children with ES were between 5 and 16 years, and between 5 and 15 years in the control group. Periventricular white matter hyperintensities were observed in 3 patients. On MR spectroscopy study, significantly lower levels of Choline metabolite (Cho) were detected in the frontal subcortical region and thalamus regions of the patients compared with the control group. There was no statistically significant difference between the levels of other metabolites (NAA, Cr, mI and Glx). In the lentiform nucleus, although the average value of Cho in ES patients was lower than that of the control group, it was not statistically significant. Conclusion Cho metabolite was determined to have an important role in brain metabolism in Eisenmenger syndrome patients. Oral Cho treatment may help to extend survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect